Horizon Pharma acquires Raptor Pharma and with it Procysbi and Quinsair

Horizon Pharma plc and Raptor Pharmaceutical Corp. announced the companies have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. common stock for $9.00 per share in cash, for an implied fully diluted equity value of approximately $800 million. The transaction is expected to close in the fourth quarter of 2016. Strategic and financial benefits of the transaction: � Strengthens Horizon's focus on rare diseases and provides expansion into Europe and other international markets. � Adds Procysbi delayed-release capsules and Quinsair (aerosolized form of levofloxacin) global rights, with Procysbi having strong patent protection through 2034.